Aeglea Biotherapeutics was founded in 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. Aeglea's pipeline includes AEB1102 for hyperargininemia and cancer, and three additional drug candidates in pre-clinical development targeting various metabolic disorders and malignancies.
Market
Pharmaceuticals
Location
Austin,
Texas,
USA
Coinvestors
Ally Bridge Group, Cowen Investments, Jennison Associates, Novartis Venture Funds, OrbiMed Advisors, RA Capital, Rock Springs Capital, UT Horizon Fund, Venrock